July 02, 2012
1 min read
Save

Long-term data show safety and efficacy of angle-supported phakic IOL

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

ROME — Long-term data show that the AcrySof Cachet phakic IOL is safe and effective in the correction of high myopia, according to one surgeon.

“The Cachet has become my standard for high myopia, and I use it in thin corneas for –6 D or higher,” Michael Knorz, MD, said at the joint Refractive.online and SICCSO meeting.

Michael Knorz

Michael Knorz

The first Cachet IOL (Alcon) was implanted in 1999, and the lens has passed the test of time regarding the two main concerns of angle-supported lenses: endothelial cell loss and pupil ovalization.

“The secret of the success of this lens compared to previous models is the soft material that makes the lens adapt to the anatomy of the eye and overcome the crucial issue of sizing,” Knorz said.

Endothelial cell loss is about 1% per year, which is below the limit of 2% established by the ISO standards for phakic IOLs.

Official data have reached 5 years of follow-up with 165 eyes. Visual results are excellent, with almost all patients either gaining or not losing lines. Mean refraction improved from –10 D to –0.25 D, and it has been stable over the 5 years of follow-up. More than 96% of patients were satisfied at 1 year and 5 years.

Alcon has extended the study on the Cachet to 8 years, closely monitoring the patients yearly.

“I also see my patients at least every year,” Knorz said.

Since he started implanting the Cachet lens, his number of phakic IOL implantation procedures has more than doubled, he said.

  • Disclosure: Knorz is a consultant for Alcon.